RISS 검색 - 국내학술지논문 상세보기

다국어 초록 (Multilingual Abstract)

Background/Aims: This study investigated the antiviral effects of tenofovir disoproxil fumarate (TDF) monotherapy in nucleos(t)ide analogue (NA)-naive and NA-experienced chronic hepatitis B (CHB) patients.
Methods: CHB patients treated with TDF monotherapy (300 mg/day) for ≥12 weeks between December 2012 and July 2014 at a single center were retrospectively enrolled. Clinical, biochemical, and virological parameters were assessed every 12 weeks.
Results: In total, 136 patients (median age 49 years, 96 males, 94 HBeAg positive, and 51 with liver cirrhosis) were included. Sixty-two patients were nucleos(t)ide (NA)-naïve, and 74 patients had prior NA therapy (NA-exp group), and 31 patients in the NA-exp group had lamivudine (LAM)-resistance (LAM-R group). The baseline serum hepatitis B virus (HBV) DNA level was 4.9±2.3 log IU/mL (mean±SD ), and was higher in the NA-naïve group than in the NA-exp and LAM-R groups (5.9±2.0 log IU/mL vs 3.9±2.0 log IU/mL vs 4.2±1.7 log IU/mL, P<0.01). The complete virological response (CVR) rate at week 48 in the NA-naïve group (71.4%) did not differ significantly from those in the NA-exp (71.3%) and LAM-R (66.1%) groups. In multivariate analysis, baseline serum HBV DNA was the only predictive factor for a CVR at week 48 (hazard ratio, 0.809; 95% confidence interval, 0.729–0.898), while the CVR rate did not differ with the NA experience.
Conclusions: TDF monotherapy was effective for CHB treatment irrespective of prior NA treatment or LAM resistance. Baseline serum HBV DNA was the independent predictive factor for a CVR. (Clin Mol Hepatol 2015;21:41-48)

참고문헌 (Reference)

1 최강혁, "약제 내성 만성 B형간염 환자에서 테노포비어를 포함한 구원치료의 효과" 대한소화기학회 65 (65): 35-42, 2015

2 Berg T, "Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection" 139 : 1207-1217, 2010

3 van Bommel F, "Tenofovir for patients with lamivudine-resistant hepatitis B virus(HBV)infection and high HBV DNA level during adefovir therapy" 44 : 318-325, 2006

4 Marcellin P, "Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B" 359 : 2442-2455, 2008

5 Patterson SJ, "Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B" 60 : 247-254, 2011

6 안성수, "Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a singlecenter cohort" 대한간학회 20 (20): 261-266, 2014

7 Fung S, "Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (>/= 9 log copies/ml)" 2014

8 Woo G, "Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B : a systematic review and Bayesian meta-analyses" 139 : 1218-1229, 2010

9 Mommeja-Marin H, "Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection : analysis and review of the literature" 37 : 1309-1319, 2003

10 Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level" 295 : 65-73, 2006